Alba Equity is an investment syndicate based in Aberdeen that funds businesses with high growth potential. The group contributes member experience and connections alongside capital.
The Edinburgh biotech uses the capital to scale its 3D bioprinted tumour models across the UK, Europe, and the US.
"Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to accelerate oncology drug development significantly."
The Scottish National Investment Bank led the Series A round to accelerate clinical validation and regulatory submission of the company's respiratory monitoring platform.
"We are delighted to close this round and thank both our existing investors and the Scottish National Investment Bank for their support,"
TRICAPITAL led the investment round with backing from a syndicate of Scottish investors.
"Our next phase of growth will involve building international partnerships, growing the team, and appointing a scientific advisory committee to support the work of the main board."
The funding includes backing from Equity Gap, SIS Ventures, Alba Equity, the Scottish Investment Bank and Innovate UK.
"This is such an important milestone for Trojan Energy. Ever since we started this business, we have wanted to ensure that the benefits of the low carbon transition can be realised by everyone and not just those with a driveway. With this investment, our vision has moved a step closer. The rewards for our customers and our planet will be massive and prove the point that a big idea and great engineering can change the world."